TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07570316: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyro

Sponsor: argenx · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 230 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,795,976

Rescue Site Savings

+$7,118,744

Unlock Full NCT07570316 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07570316 Rescue Dossier →